Pulsenmore Ltd. entered into a securities purchase agreement on June 25, 2026, to issue and sell pre-funded warrants and ordinary warrants to an institutional investor for approximately $7.5 million in gross proceeds. The offering of up to 1,562,500 ordinary shares via warrants, priced at $4.7999 per warrant unit, is expected to close on or about June 26, 2026. The company intends to use the net proceeds for marketing, commercialization, and working capital. Pulsenmore Ltd. operates in the medical technology industry, providing remote monitoring solutions for patients with sleep apnea.
